Christel Hero, MD, of Sahlgrenska University Hospital in Gothenburg, Sweden, and colleagues reported that, LDL had modest associations with development of cardiovascular disease but no consistent dose-response above the 100 mg/dL threshold for statin treatment in this population.
In type 1 diabetes patients already on statins, LDL levels didn't have any significant link to subsequent cardiovascular disease in the Swedish National Diabetes Register data.
The cholesterol-to-HDL ratio had likewise modest links to cardiovascular disease in patients on or off lipid medications, but with a consistent rise in risk across categories.
Hero added, "The ratio of cholesterol-to-HDL is a more reliable marker for risk when considering primary prevention."
Fernando Ovalle, MD, director of the Comprehensive Diabetes Center of the University of Alabama at Birmingham, commented, "The findings emphasized how much remains unknown about cardiovascular disease in type 1 diabetes."
"We made a lot of assumptions and jumped to a lot of conclusions that the markers of cardiovascular disease and treatments for prevention of cardiovascular diseases will be the same in type 1 -- and that just may not be the case." "This could potentially change the perspective on how we see the use of statins and the assessment of cardiovascular risk in general."
Elizabeth Seaquist, MD, ADA president for medicine and science and a moderator at the session cautioned, "Don't toss out LDL in clinical practice just yet." Dr. Seaquist continued saying that LDL may not be as strong a predictor for cardiovascular disease as in type 2, as has been suspected from prior studies, but further research is needed to determine what to use in the clinic. "These patients are still at great risk for cardiovascular events, and we need to make certain that we're doing the right things to prevent that," she said. "It will help us if we were to do a trial to determine the benefits of lipid-lowering in type 1 patients, how we might design it. They don't have particularly high LDLs in general."
Elizabeth Seaquist is not for "tossing out LDL in clinical practice" yet, maybe I'm an old cynic but could it be conflicts of interest that's behind that statement ?
Dr Seaquist reported serving as a board member and President Elect of
Science and Medicine for the American Diabetes Association; serving as a consultant for AMG Medical, sanofi-aventis, SkyePharma, and Merck; receiving grants or grants pending from the American Diabetes Association, Eli Lilly, and the National Institutes of Health; and receiving payment for lectures from the Japan Diabetes Society, the American Diabetes Association, Intellyst Medical Education, Pediatric Academic Societies, the Association of Specialty Professors, and the International Society for Neurochemistry
Graham
No comments:
Post a Comment